YN014 / Innogen Pharmaceutical Technology - LARVOL DELTA

Future development and outlook for 2026 (HKEXnews) - "Subject to Phase III data readout and regulatory progress, the Group plans to initiate pre-launch preparation for the weight management indication. Following the readout of Phase III clinical data, the Group will evaluate product positioning, target patient population, patient education and commercialisation planning for the indication....In addition, the Group will also continue to advance its T1D and AD programs. Both programs are currently in the IND-enabling stage and are expected to progress toward IND submission in 2026, subject to development progress and regulatory approval."

Commercial • IND • Alzheimer's Disease • Obesity • Type 1 Diabetes Mellitus